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ABSTRACT 23 
Histamine intolerance is a disorder in the homeostasis of histamine due to a reduced intestinal 24 
degradation of this amine, mainly caused by a deficiency in the enzyme diamine oxidase (DAO). 25 
Among the several multifaced symptoms associated with histamine intolerance, headache is one 26 
of the most recognised and disabling consequences. The aim of this study was to determine the 27 
prevalence of DAO deficiency in patients with a confirmed migraine diagnosis according to the 28 
current International Headache Society (IHS) and in non-migraine subjects. DAO activity was 29 
assessed in a total of 198 volunteers recruited at the Headache Unit of the Hospital General de 30 
Catalunya, 137 in the migraine group and 61 as a control group. DAO enzyme activity in blood 31 
samples was determined by ELISA test. Values below 80 HDU/ml (Histamine Degrading Unit/ml) 32 
were considered as DAO deficient. Mean value of DAO activity from migraine population (64.5 33 
±33.5 HDU/ml) was significantly lower (p<0.0001) than that obtained from healthy volunteers 34 
(91.9 ± 44.3 HDU/ml). DAO deficiency was more prevalent in migraine patients than in the control 35 
group. A high incidence rate of DAO deficiency (87%) was observed in the group of patients with 36 
migraine. On the other hand, 44% of non-migranous subjects had levels of DAO activity lower 37 
than 80 HDU/ml. Despite the multifactorial etiology of migraine, these results seem to indicate 38 
that this enzymatic deficit could be related to the onset of migraine. 39 
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INTRODUCTION 45 
Diamine oxidase (DAO), also called histaminase, is one of the main enzymes in the metabolism of 46 
histamine, playing an important role in the degradation of this amine in the intestinal epithelium, 47 
regulating its passage into the systemic circulation. A reduced DAO activity could be one of the 48 
causes of histamine intolerance, a disorder in the homeostasis of histamine, which provokes the 49 
accumulation of this amine in plasma and the appearance of multi-faced allergy-like clinical 50 
symptoms. DAO deficiency may be the result of a genetic mutation [1,7] or related to certain 51 
diseases that limit the secretion of this enzyme, especially inflammatory or degenerative 52 
intestinal disorders [9,15]. Finally, certain medications can also cause a specific and reversible 53 
inhibition of DAO activity [14,17]. 54 
Unlike the well-known histamine intoxication, appearing after consumption of products with high 55 
histamine contents, histamine intolerance symptoms may appear even after the intake of low 56 
amounts of this amine [5]. Consequently, the dietary management is the main clinical tool to 57 
prevent the symptomatology related to histamine intolerance, based on the follow up of 58 
histamine free diets [3,24,29,30]. Apart from histamine, the presence of other bioactive amines, 59 
such as putrescine, could be co-responsible of the triggering of adverse health effects by 60 
competing for the same metabolic pathway [4,14]. In addition, although there is lack of evidence 61 
about the mechanism, certain foods have been associated with an endogenous ability to release 62 
histamine, such as egg white, citrus, chocolate and crustaceans [27]. More recently, the 63 
supplementation with exogenous DAO enzyme has been postulated as a complementary 64 
preventive treatment for histamine intolerance, improving the quality of life of patients 65 
undergoing those dietary restrictions [13,14]. 66 
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Symptoms associated with the accumulation of histamine in plasma may occur due to the actions 67 
of histamine in multiple organs according to the expression of histamine receptors, including 68 
gastrointestinal tract, lung, skin, cardiovascular system and brain. Therefore, the main symptoms 69 
described for histamine intolerance are headache, flatulence, diarrhea, abdominal pain, sneezing, 70 
rhinorrhea, hypotonia, arrhythmias, idiopathic urticaria and pruritus [14,17]. Although there is no 71 
general consensus on histamine intolerance diagnosis, the most commonly used diagnostic 72 
algorithm includes the presentation of at least two of these symptoms and the clinical 73 
improvement after following a histamine-free diet. Negative results for food allergen specific IgE 74 
are also required [14,17]. 75 
Headache is one of the most recognised and disabling consequences of histamine intolerance 76 
[25,31]. Migraine is a chronic neurovascular disorder that may be caused by several triggers 77 
(physiological, hormonal, behavioural, environmental and nutritional) as has been recently 78 
reported by Kokavec [12]. In patients diagnosed with migraine, increased plasmatic levels of 79 
histamine were reported during and among attacks [14]. According to Maintz and Novak [17], the 80 
association between headache and DAO deficit could be explained because the enzymatic 81 
deficiency would provoke an increase of plasmatic histamine that would be responsible for the 82 
appearance of headaches by releasing nitric oxide upon stimulation of H1R receptors found in 83 
intracranial arteries. In addition, a high DAO production by the placenta could potentially explain 84 
the improvement of migraine that some women experience during pregnancy [18]. 85 
Clinical studies have shown an association between a reduced DAO activity and some of the 86 
above-mentioned symptoms related to histamine intolerance. Mušič et al. [22] reported that 80% 87 
of 316 patients with suspected histamine intolerance showed a reduced serum DAO activity. 88 
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Moreover, mean DAO activity levels of these patients were significantly lower than in healthy 89 
controls. Likewise, the study carried out by Manzotti et al. [19] evaluated DAO activity in 14 90 
patients with a potential diagnosis for histamine intolerance, with the most reported symptoms 91 
being functional bloating, abdominal pain, tachycardia, diarrhea, headache, pruritus, flushing, 92 
rhinorrhea or nausea. In this case, it was found that 71% of patients had serum DAO activity under 93 
the threshold considered as cut-off for histamine intolerance with a mean DAO activity value 94 
significantly lower than healthy controls. Apart from these studies dealing with patients with 95 
coexisting histamine intolerance symptoms, other clinical studies have correlated DAO deficiency 96 
with some specific pathologies, mainly gastrointestinal and dermatological complaints 97 
[6,8,9,16,21,23,25,26]. However, according to our knowledge, there is little information available 98 
about serum DAO levels in patients clinically diagnosed with migraine. The aim of this study was 99 
to determine the prevalence of DAO deficiency in patients with a confirmed episodic migraine 100 
diagnosis according to the current International Headache Society (IHS) and in non-migraine 101 
subjects. 102 
 103 
MATERIAL AND METHODS 104 
Subjects of the study 105 
The study was performed in the Headache Unit of the Hospital General de Catalunya (Sant Cugat 106 
del Vallés, Barcelona, Spain) with a total of 198 adult volunteers aged between 18 and 65 years. 107 
Episodic migraine, as established by the IHS in the International Classification of Headache 108 
Disorders, is mainly characterized by the presence of 0 to 14 headache days per month. Two 109 
different groups were considered: a migraine group including 137 patients (122 females [89%] 110 
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and 15 males [11%]) diagnosed according to current IHS criteria [10], and a control group of 61 111 
volunteers (34 females [56%] and 27 males [44%]) without clinical criteria for migraine. For the 112 
migraine group, individuals with the onset of migraine over 50 years old, the diagnosis of other 113 
kind of headache, the possibility of pregnancy and the following of a preventive treatment for 114 
episodic migraine during three months prior to the study were excluded. The mean age of 115 
patients with migraine was 41.95 (±11.3) years and for control volunteers it was 42.46 (±14.4) 116 
years (Table 1). 117 
The Ethics Committee of the Hospital General de Catalunya approved the study and all 118 
participants signed an informed consent form. This study is listed on the ISRCTN registry with trial 119 
ID ISRCTN10091019. 120 
 121 
DAO activity analysis 122 
Blood samples were collected from all subjects by venipuncture in an EDTA tube after an 8-hour 123 
fasting period and samples were analysed with ELISA to determine DAO enzyme activity in 124 
accordance with the manufacturer instructions (D-HIT, Sciotec, Austria). This method was 125 
previously used for the same purpose by Mušič et al. [22]. Values above 80 HDU/ml (Histamine 126 
Degrading Unit/ml) were considered normal while values below 80 HDU/ml were considered DAO 127 
deficient. One HDU corresponds to the DAO activity that degrades 1 pmol/ml of histamine.  128 
 129 
Statistical analysis 130 
Data distribution and statistical analysis was performed using SPSS for Windows, version 22 131 
(Chicago, IL). Data distribution was obtained using the Kolmogorv-Smirnov test. As data were not 132 
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normally distributed, Mann-Whitney test was used to compare DAO activity between both 133 
groups. Probability values of p<0.05 were accepted as significant. 134 
 135 
RESULTS  136 
The prevalence of DAO deficiency (<80 HDU/ml) assessed in migraine patients and individuals 137 
without clinical criteria for migraine as control group is shown in figure 1A. A high prevalence of 138 
DAO deficiency was observed in the migraine group with 87% of subjects with this enzymatic 139 
deficiency in comparison to 44% in the control group. Within the migraine group, the percentage 140 
of individuals that showed normal DAO activity levels was 13%. Figure 1B shows the proportion 141 
of DAO deficiency in the migraine group by gender. Although the number of women included in 142 
the study was higher than men, DAO deficiency was similar in both cases (86% and 90%). 143 
Figure 2 shows the mean DAO activity (±SD) obtained for both study groups. Mean DAO activity 144 
in migraine population was 64.5 ±33.5 HDU/ml, being significantly lower (Mann-Whitney U 145 
value=2090.5, Wilcoxon W value=11001.5, p<0.0001) than that obtained from control volunteers 146 
(91.9 ± 44.3 HDU/ml). Additionally, figure 3 graphically shows the distribution of DAO activity 147 
values in both groups. It seems important to highlight that the variability of DAO activity values 148 
observed in migraine patients is low, with 50% of cases comprised from 49.5 to 67.1 HDU/ml 149 
(percentile 25 and percentile 75, respectively). However, in this group some extremely high 150 
values, statistically considered as outliers, were recorded, reaching DAO activity values close to 151 
250 HDU/ml. On the other hand, greater variability was found in DAO activity values from control 152 
individuals. For this group, the interquartile range, calculated as the difference between 153 
percentile 75 (118.5 HDU/ml) and percentile 25 (59.80 HDU/ml), was 58.7 HDU/ml, three fold 154 
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higher than the interquartile range obtained for migraine group (17.6 HDU/ml). Similarly to the 155 
migraine group, some atypically high DAO activity values were found, with maximum levels up to 156 
211 HDU/ml. 157 
 158 
DISCUSSION 159 
Headache has been reported as one of the most prevalent and disabling disturbances associated 160 
with an excess of histamine based on a deficit of DAO [17]. Back in 1993, Wantke et al. [29] 161 
described that headaches of 33 out of 45 patients decreased in frequency, duration and intensity 162 
after four weeks of avoiding histamine-rich foods, such as fish, cheese, hard cured sausages, 163 
pickled cabbage and alcoholic beverages. These authors hypothesised that a diminished 164 
histamine degradation based on a deficiency of DAO could be the cause of this food intolerance. 165 
Recently, a relationship between functional SNPs in the DAO gene and the risk for migraine has 166 
been proposed. García-Martín et al. [7] studied the frequency of four different genotypes and 167 
allelic variants in 197 patients with migraine and 245 healthy controls from Spain. The DAO SNP 168 
rs10156191, associated with decreased DAO enzyme activity, seemed to be more frequent in the 169 
migraine population. In the same vein, another study performed by Meza-Velázquez et al. [20] 170 
also found that a mutant DAO SNP was significantly more frequent in a group of women with 171 
migraine than in the control group. Despite that published studies seem to indicate that DAO 172 
deficit could be one of the triggers for headaches, data about serum DAO activity levels in affected 173 
populations would be important to support this association.  174 
In this work, serum DAO activity was studied in patients diagnosed with migraine in comparison 175 
with a non-migranous population. The prevalence of DAO deficiency within migraine patients was 176 
  9 
elevated, finding that 87% of these individuals had serum DAO levels below the cut-off value of 177 
80 HDU/ml (Figure 1A). DAO deficiency was not found to be higher in women (Figure 1B) despite 178 
several authors have associated DAO levels with some female sex hormonal changes (11,14). 179 
Moreover, the mean value of DAO activity in migraine group was significantly lower than that 180 
obtained in the control group (Figure 2). These results point out that this enzymatic deficit could 181 
be related to the onset of migraine. On the other hand, the fact that 13% of migraine patients 182 
showed normal DAO activity levels evidenced that this enzymatic deficiency could be one of the 183 
triggers of migraine but not the single trigger responsible for this pathology with multifactorial 184 
etiology. 185 
In the control group, 44% of volunteers showed DAO enzyme deficiency but absence of migraine. 186 
As was previously mentioned, impaired intestinal histamine degradation by a deficit of DAO leads 187 
to the appearance of multifaced clinical symptoms, which can coexist in histamine intolerants. In 188 
fact, headache is just one of the many symptoms associated with this intolerance. Unfortunately, 189 
no other symptoms were recorded in this study and therefore, it can not be concluded that those 190 
individuals were actually asymptomatic for histamine intolerance. 191 
It also has to be stated that DAO activity values found in the control group were more variable 192 
than those reported by migraine patients. This wide variability was also observed in the study 193 
performed by Manzotti et al. [19], which reported a larger range of DAO activity values for the 194 
cohort of healthy controls than in individuals suffering from histamine intolerance. 195 
As in the present work, other clinical studies have been focused in the evaluation of serum DAO 196 
activity in specific pathologies (Table 2). In a previous study also focusing on neurological 197 
symptomatology, Steinbrecher and Jarisch [25] described that 23 out of 27 potential histamine 198 
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intolerant patients suffering from headache (85%) had decreased DAO levels. Furthermore, after 199 
4 weeks of histamine-free diet, a significant rise in DAO activity was noted and the majority of 200 
patients reported a complete remission or improvement in headache frequency. 201 
Considering dermatological symptoms, Maintz et al. [16] evaluated serum DAO activity in patients 202 
with atopic eczema in comparison with histamine-intolerant patients without atopic eczema and 203 
also with healthy volunteers. No individuals with this enzymatic deficiency were found in the 204 
healthy control group. On the contrary, the percentage of patients with DAO deficiency was 19% 205 
in atopic eczema group and 20% in histamine intolerants without this dermatological affectation. 206 
Thus, both a significantly lower mean DAO activity and a higher total number of individuals with 207 
a reduced DAO activity was found in atopic eczema patients and histamine intolerants without 208 
atopic eczema in comparison with healthy controls. In another study that considered patients 209 
with chronic spontaneous urticaria accompanied by gastrointestinal disturbances, a prevalence 210 
of DAO deficiency of 44% was observed [28]. Conversely, other studies involving patients with 211 
atopic dermatitis and urticaria did not find statistically significant association between a reduced 212 
DAO activity and high plasma histamine levels in patients suffering from these skin diseases 213 
[2,30]. 214 
In the field of gastrointestinal disorders, Honzawa et al. [9] evaluated the clinical significance of 215 
serum DAO activity in 98 patients with inflammatory bowel disease. This study demonstrated that 216 
DAO activity was significantly lower in patients with Crohn’s disease or ulcerative colitis than in 217 
healthy controls, indicating a relationship between DAO levels and intestinal permeability. 218 
Furthermore, Enko et al. [6] measured serum DAO levels in 121 patients with lactose 219 
malabsorption, finding that 36.4% of this cohort showed a deficiency in this enzyme. Additionally, 220 
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it was observed that individuals with lactose malabsorption and deficit of DAO tended to report 221 
more gastrointestinal symptoms during the lactose hydrogen breast test than those with normal 222 
DAO activity. Other authors concluded that low serum DAO activity levels could act as indicator 223 
of intestinal mucosal disturbances in patients with anorexia nervosa [26] or under chemotherapy 224 
treatment [21]. 225 
In clinical studies dealing with paediatric populations, an observational retrospective study 226 
performed by Rosell-Camps et al. [23] that involved 16 children with abdominal pain, chronic 227 
diarrhea and vomiting, found a direct relation between reduced serum DAO levels and these 228 
digestive complaints. Concretely, 88% of these paediatric patients showed DAO deficiency. More 229 
recently, in an observational study performed by Hoffmann et al. [8] in 394 children with chronic 230 
abdominal pain, only 8% showed DAO activity levels under the normal threshold. 231 
The high prevalence of DAO deficiency in migraine patients found in the current study (87%) 232 
coincides with that described by Steinbrecher and Jarisch [25] in patients with headache (85%) 233 
and by Rosell-Camps et al. [23] in paediatric patients with digestive complaints (88%). Moreover, 234 
these percentages are in good agreement with those described by Mušič et al. [22] and Manzotti 235 
et al. [19], which considered patients clinically suspected as histamine intolerants with diverse 236 
coexisting symptoms (Table 2). However, other studies addressing different specific pathologies, 237 
such as atopic eczema, chronic urticaria, lactose malabsorption and chronic abdominal pain, 238 
reported lower percentages of DAO deficit, with values ranging between 8% and 57% 239 
[2,6,8,16,28]. 240 
In view of the results of this study, it can be concluded that DAO deficiency is more prevalent in 241 
migraine patients than in non-migranous individuals. More studies are needed to better establish 242 
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the cut off value of DAO activity to allow not only a more accurate diagnosis of histamine 243 
intolerance but also to potentially become an additional diagnosis criterion for migraine. Likewise, 244 
further research is necessary to reasonably explain the variability found in serum DAO activity 245 
levels. 246 
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Figure captions 347 
Fig. 1 Percentage of individuals with deficiency (<80 HDU/ml, red) and normal (>80 HDU/ml, 348 
green) DAO activity in both study groups (A) and depending on the gender in the migraine group 349 
(B). 350 
Fig. 2 DAO activity (mean ±SD) in migraine patients and individuals without clinical criteria for 351 
migraine as control group. A Mann-Whitney test was applied to compare DAO activity in both 352 
groups, *p<0.0001. 353 
Fig. 3 Distribution of DAO activity in migraine patients and individuals without clinical criteria for 354 
migraine as control group. The bottom and top of the box (interquartile range) are the percentile 355 
25 and the percentile 75, respectively. Central line represents the median. Lines extending 356 
vertically from the boxes (whiskers) indicate variability outside the interquartile range. Values 357 
statistically considered as outliers are plotted as circles (atipycal value) or asterisks (extremely 358 
atypical value) 359 
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Table 1. Information about study subjects including migraine and control groups. 
 
	
Characteristic Migraine-group Control-group
N 137 61
Age-(Mean) 41.95 42.46
Gender)(%)
Female 89 56
Male 11 44
		
Table 2. Summary of the studies that measured serum DAO activity levels in patients with generic symptoms potentially related to histamine 
intolerance or other specific pathologies. 
 
 	
a Reduced DAO activity <10 U/mL. 
Reference Pathology Study2subjects %2of2DAO2
deficiency DAO2activity
a
3162patients2with2clinically2suspected2histamine2intolerance 80 D
552healthy2controls 22 D
142patients2with2clinically2suspected2histamine2intolerance 71 7.04
342healthy2controls D 39.5
25 Headache 352histamine2intolerant2patients2with2headache 85 D
1622patients2with2atopic2eczema 19 D
1242patients2with2symptoms2of2histamine2intolerance2but2without2atopic2eczema 20 D
852healthy2controls 0 D
28 Chronic2spontaneus2urticaria 552patients2suffering2for2chronic2urticaria2and2gastrointestinal2disturbances 44 17.8
582patients2with2atopic2dermatitis D 10
192healthy2controls D 14
752patients2with2chronic2idiopathic2urticaria 57 D
252healthy2controls 40 D
552patients2with2Crohn's2Disease D 8.5
432patients2with2Ulcerative2Colitis D 8.9
172healthy2controls D 10.3
6 Lactose2malabsorption 1212patients2with2lactose2malabsorption 36 13.6
212patients2with2anorexia2nervosa2restricting2type D 8.2
152patients2with2anorexia2nervosa2bingeDeating/purging2type D 12.3
202healthy2controls D 12.1
21 Damage2of2intestinal2mucosa 202patients2with2unresectable2metastatic2gastric2cancer D 2.4
23 Chronic2digestive2complaints 162paediatric2patients2diagnosed2with2two2or2more2digestive2complaints 88 D
8 Chronic2abdominal2pain 3942paediatric2patients2 8 4.5
Damage2of2intestinal2mucosa26
22 Generic2symptoms2of2histamine2
intolerance
Generic2symptoms2of2histamine2
intolerance
19
Inflammatory2Bowel2Diseases
Atopic2Eczema16
9
Atopic2Dermatitis30
2 Chronic2Idiopathic2Urticaria
